Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Exelixis and Bristol-Myers Squibb (BMY) enter into clinical development collaboration to evaluate CABOMETYX with Opdivo (21.69)The co and Bristol-Myers Squibb Company (<strong>BMY</strong>) announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX (cabozantinib), Exelixis' small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab). The clinical development program, which will be co-funded by the companies, is expected to include a phase 3 pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma (HCC), and potentially other tumor types.</td> </tr></table>"